oncliveMay 151 min read

Durvalumab Plus BCG Reduces High-Risk NMIBC Recurrence or Death Risk by 32% in Phase 3 POTOMAC Trial

Durvalumab plus BCG induction and maintenance yielded an HR of 0.68 vs BCG alone for DFS in BCG-naive, high-risk non–muscle-invasive bladder cancer.

source

Reporting by onclive. The original article may no longer be reachable at its published URL.

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

oncliveMay 151 min read

Durvalumab plus BCG induction and maintenance yielded an HR of 0.68 vs BCG alone for DFS in BCG-naive, high-risk non–muscle-invasive bladder cancer.

source

Reporting by onclive. The original article may no longer be reachable at its published URL.